Healthcare Strategy + AI Execution

Accelerating Healthcare Innovation: From Strategic Insight to Deal Execution.

An AI-enabled commercialization and market access partner exclusively for global Biotech, Medtech, and Life Sciences. We bridge the gap between US and Asia markets with data-driven strategy, proprietary BD intelligence, and elite execution.

Cross-Border Expertise

AI-Enabled Intelligence

Results-Oriented Execution

Book a Strategy Diagnosis Explore Our Capabilities
Los Angeles Shanghai Beijing Taipei
Pfizer Roche NOVARTIS Abbott Bayer sanofi Takeda

Heritage & Positioning

Born from the Best, Built for You.

We are not a traditional CRO. Aplus Consultant is a premium, hybrid strategy execution partner and intelligence platform.

Our team is comprised of elite strategists and industry veterans drawn from the world's top-tier consulting firms, including Deloitte, PwC, IQVIA, and IBM. We bring the rigorous, data-driven DNA of these global institutions into a specialized, agile boutique environment.

Today, we serve as the connective tissue between scientific evidence and commercial reality. By combining rNPV financial modeling with an unparalleled network of healthcare experts, we bridge the gap between US and Asia markets.

100+

Global Projects Completed

150k+

Global KOL & Expert Network

Executive Strategy Meeting

Data-Driven Strategy

rNPV Modeling & Access

The Growth Engine

Core Capabilities

Market Access & US Entry

Navigate complex US payer landscapes, Medicare differences, and PBM dynamics. Align clinical data with HEOR to secure coding and pricing.

Outcome: Frictionless penetration with a validated roadmap.

Licensing & Partnering

End-to-end deal advisory, cross-border licensing, and joint ventures utilizing advanced risk-adjusted Net Present Value (rNPV) modeling.

Outcome: Maximized asset valuation & secured global deals.

AI-Driven BD Intel

Deploy proprietary AI to identify and rank priority targets—from C-suite decision-makers to tier-1 Key Opinion Leaders (KOLs).

Outcome: 60% faster lead generation & precise mapping.

Commercial Execution

Operationalize strategy. Establish virtual data rooms and execute rapid 4-week "BD Sprints" targeting institutional buyers.

Outcome: Rapid pipeline conversion to executed agreements.

Engagement Model

Built for Speed. Driven by Outcomes.

1

Diagnose & Model

Weeks 1-2

QuickScan market research, rNPV alignment, and gap analysis.

2

Target & Architect

Weeks 3-4

AI target list generation, commercial narrative, and VDR structuring.

3

Execute & Convert

Weeks 5-8+

Active BD outreach, executive meetings, and term sheet negotiation.

Executive Team

Led by Industry Veterans

HL

Howard Lei

Managing Director

20+ years experience with IMS Health, PwC, Deloitte, and IBM. Specialized in pricing and market access strategy.

HW

Helen Wu

Director

Extensive leadership in global consulting, specializing in cross-border alliances and medical asset valuation.

Technical Advantage

Intelligence Layer for BD

Powered by a proprietary AI platform. We utilize generative AI and dynamic data integration to give our clients an asymmetric informational advantage.

  • Predictive Partner Matching

    AI identifies Biopharma players most likely to acquire or license your asset based on pipeline gaps.

  • Zero-Hallucination Retrieval (RAG)

    Transform clinical data into a secure, instantly queryable private intelligence hub.

KOL Target Mapping
Match Accuracy: 98%
Dr. Sarah Jenkins
MD Anderson Cancer Center
Score: 94
Dr. Michael Chen
Dana-Farber Institute
Score: 89

Who We Empower

Built for Life Science Leaders

🧬

Clinical-Stage Biotech

Seeking rNPV asset valuation and clinical advisory board formation.

🏥

MedTech & Devices

Requiring clear CPT reimbursement pathways and hospital access.

🌏

Asia-Pacific Innovators

De-risked Go-To-Market strategies to enter the US market.

📈

Life Science Investors

Needing rapid, rigorous commercial due diligence before deployment.

Proof of Execution

Case Studies

Strategy & Valuation

US Access for Alzheimer's Asset

Built rNPV model and tested price barriers to secure $300M valuation baseline.

Outcome: Retained for final US negotiations.
Market Access & Partnering

US Entry for BGM Device

Analyzed reimbursement dynamics and identified clinics/insurers for MedTech partnership.

Outcome: Optimal business model developed.
AI Implementation

BD Efficiency for Rare Disease CRO

Automated BD workflow with AI mapping, identifying 300+ global partners.

Outcome: 60% lead gen efficiency gain.
Flagship Report

2026 Global Healthcare Commercialization Whitepaper

Analysis of Biotech rNPV valuation reshaping, US PBM integration, and healthcare AI ROI traps.

Request PDF

Capabilities

Downloadable Service Flyers

Strategic Advisory

BD strategy, licensing, and asset evaluation models for global partnerships.

Download Flyer

Market Intelligence

Expert interviews and precise KOL network identification across US/China.

Download Flyer

AI Growth Infrastructure

AI consulting and workflow automation integrated with CRM platforms.

Download Flyer

Growth Strategy

Crafting tailored access strategies to penetrate new markets and build traction.

Download Flyer

From Uncertainty to a Clear Roadmap.

Assess valuation parameters and evaluate US entry risks in 30 minutes.

Select a Time (Calendly)

Contact us at bd@consultantaplus.com